Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Fenhuma 400 microgram sublingual tablets

Active Ingredient:
fentanyl citrate
Company:  
Glenmark Pharmaceuticals Europe Ltd See contact details
ATC code: 
N02AB03
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials HCP Med Info
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

Important risk minimisation information for healthcare professionals about treatment on Fenhuma

{healthcare_pro_orange} For Healthcare Professionals

The Fenhuma® Prescriber Guide is designed to support healthcare professionals

in the diagnosis of breakthrough pain (BTP) in patients suffering from cancer. It

provides guidance on the initiation, administration and titration of Fenhuma ® and

promotes engagement with patients and their carers. The booklet should be

used in conjunction with the Fenhuma ® Summary of Product Characteristics

(SPC).

{pdf_link}

Important risk minimisation information for patients and their carers about treatment on Fenhuma

Booklet - Important risk minimisation information for patients and their carers

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Glenmark Pharmaceuticals Europe Ltd
Company image
Address
Building 2, Croxley Park, Watford, WD18 8YA
Telephone
+44 (0)1923 202 950
Fax
+44 (0)1923 251137
Medical Information Direct Line
0800 458 0383
E-mail
[email protected]
Stock Availability
+44 (0)1923 202 950
WWW
www.glenmarkpharma.com